Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ903MR)

This product GTTS-WQ903MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ903MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ416MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ10206MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ13110MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ12753MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ10725MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ9574MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15959MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ12036MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW